Clinical Trial Update: MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MDX-010 (tremelimumab) alone, MDX-1379 vaccine alone, or their combination in patients with unresectable or metastatic melanoma; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MDX-010 (tremelimumab) (tremelimumab)
• MDX-1379

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma, Metastases | Phase 3 | Status: COMPLETED | Results posted: 2011-06-23